Related Experiment Video
Updated: Feb 22, 2026
19:15
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
88.1K
Developmental Pharmacokinetics in Neonates: Maturational Changes and Beyond
Karel Allegaert1, Paola Mian1, John N van den Anker2
1Intensive Care and Department of Pediatric Surgery, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands.
Current Pharmaceutical Design
|September 28, 2017
Summary
Understanding neonatal pharmacokinetics (PK) and pharmacodynamics (PD) is crucial for safe drug therapy. This study details how maturational and non-maturational factors influence drug behavior in neonates.
Area of Science:
- Neonatal pharmacology
- Pediatric pharmacokinetics
- Drug metabolism and elimination
Background:
- Effective pharmacotherapy in neonates requires understanding drug pharmacokinetics (PK) and pharmacodynamics (PD).
- Neonatal populations exhibit unique PK and PD profiles due to developmental and disease-related factors.
Purpose of the Study:
- To describe general PK aspects of drug absorption, distribution, metabolism, and elimination (ADME) in neonates.
- To emphasize the impact of both maturational and non-maturational covariates on PK variability.
- To illustrate these concepts with specific drug examples.
Main Methods:
- Review of developmental PK principles in neonates.
- Analysis of maturational covariates (age, weight) affecting ADME processes.
- Examination of non-maturational covariates (disease, treatment, genetics) influencing PK.
Main Results:
- Neonatal ADME processes undergo maturation, influenced by various covariates.
- Maturational covariates include age and weight-dependent changes.
- Non-maturational covariates encompass disease, environment, co-medications, and genetic background.
Conclusions:
- Further research should integrate existing knowledge and collect data on non-maturational covariates.
- Linking PK data with PD is essential for predicting drug effects and side effects.
- Enhanced understanding of neonatal PK/PD is clinically significant for optimizing drug therapy.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
276
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
276
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
354
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
354
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
351
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
351
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
302
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
302
01:29Drug Dosing: Infants and Children
371
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
371
01:21Factors Affecting Drug Response: Overview
3.2K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.2K